UCLA biotech spin-out ImmunGene receives $9m from life sciences investor Ally Bridge Group.
ImmunGene, a life sciences firm based in California, has raised $9m in series A backing through investment platform Ally Bridge Group. The biotech, which is developing antibody-cytokine fusion technology therapies to treat cancer, is a spin-out of the University of California Los Angeles (UCLA). ImmunGene plans to use the latest funding to advance its products…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
